StockData
Acurx Pharmaceuticals, Inc. logo

Acurx Pharmaceuticals, Inc. (ACXP) stock

ACXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.99+0.05 (+5.88%)

Close on Nov 17, 2026Market cap $5.22MP/E –Yield –

Acurx Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Acurx Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$7.67M. For fiscal 2025 it was -$8.09M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$8.09M–
FY2024Dec 31, 2024-$14.12M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.31M–
Q1 FY2026Mar 31, 2026-$1.72M–
Q4 FY2025Dec 31, 2025-$1.62M–
Q3 FY2025Sep 30, 2025-$2.03M–
Q2 FY2025Jun 30, 2025-$2.27M–
Q1 FY2025Mar 31, 2025-$2.18M–
Q4 FY2024Dec 31, 2024-$2.79M–
Q3 FY2024Sep 30, 2024-$2.83M–
Q2 FY2024Jun 30, 2024-$4.12M–

More Acurx Pharmaceuticals figures

See a number that looks wrong?